AstraZeneca today announced positive top-line results from the Phase III PINNACLE programme, which included two pivotal 24-week studies (PINNACLE 1 and PINNACLE 2) to investigate the potential of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback